These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23669150)

  • 21. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.
    Crook J; McLean M; Catton C; Yeung I; Tsihlias J; Pintilie M
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):453-60. PubMed ID: 11872292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Nakai Y; Fujii T; Hasegawa M; Fujimoto K
    Brachytherapy; 2018; 17(3):537-543. PubMed ID: 29402711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial changes of international prostate symptom score following I-125 prostate brachytherapy.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T
    Int J Clin Oncol; 2006 Aug; 11(4):320-5. PubMed ID: 16937307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study.
    Salem N; Simonian-Sauve M; Rosello R; Alzieu C; Gravis G; Maraninchi D; Bladou F
    Radiother Oncol; 2003 Feb; 66(2):159-65. PubMed ID: 12648787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the severity of acute urinary toxicity after brachytherapy with iodine-125 for localized prostate cancer.
    Takeda K; Jingu K; Koto M; Fujimoto K; Narazaki K; Kubozono M; Saito H; Yamada S; Mitsuduka K; Ishidoya S; Ariga H; Arai Y; Yamada S
    Tohoku J Exp Med; 2011 Jan; 223(1):55-60. PubMed ID: 21212603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
    Thomas C; Keyes M; Liu M; Moravan V
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
    Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
    Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
    Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
    Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.
    Henderson A; Ismail AK; Cunningham M; Aldridge S; Loverock L; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):95-104. PubMed ID: 15074730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy.
    Thomas MD; Cormack R; Tempany CM; Kumar S; Manola J; Schneider L; Hurwitz MD; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):905-8. PubMed ID: 10863058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
    Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
    BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.